



**Visiogen Announces Formation of European Subsidiary, Commencement of Controlled Commercial Release of Synchrony® Accommodating IOL**

*Multiple Scientific Presentations on Synchrony Lens, Expansion of New Clinical Sites Signals New Phase in Company Strategy*

ROME, ITALY, February 17, 2009 – Visiogen announced the formation of its European subsidiary and the commencement of the controlled commercial release of the Synchrony® accommodating intraocular lens in Europe at the winter meeting of the European Society of Cataract and Refractive Surgeons (ESCRS) held in early February in Rome, Italy. Visiogen Europe GmbH will be headquartered in Karlsruhe, Germany, and represents the company’s first overseas subsidiary.

“We are pleased with the growing interest in the Synchrony IOL in Europe and the positive European clinical results that were presented in Rome,” said Stuart Windsor, managing director of Visiogen Europe. “The establishment of a permanent Visiogen presence in Europe is evidence of our commitment to supporting our European customers, and to commercializing this exciting technology in a safe and responsible manner.”

Results of clinical research on the company’s Synchrony dual optic accommodating intraocular lens (IOL) were featured in seven platform presentations and two posters at the winter ESCRS congress. Included were initial results from new randomized controlled trials in Europe

comparing Synchrony to the ReSTOR Aspheric and TECNIS Multifocal IOLs, demonstrating favorable Synchrony performance as compared to both lenses. A notable study from the University of Heidelberg demonstrated objective dynamic accommodation with the Synchrony lens five years post-implantation. These presentations add to the growing foundation of clinical evidence on the Synchrony lens, with over 1,000 clinical trial implants to date. The Synchrony accommodating IOL has demonstrated true objective accommodation, with a mechanism of action that has been validated in multiple studies by multiple objective measures.

The Synchrony IOL is not approved for commercial marketing in the U.S. and is available only through an IDE study.

#### **About Visiogen**

Visiogen, Inc. is focused on developing innovative products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen's first commercial application, Synchrony®, a 3-dimensional dual optic accommodating intraocular lens and pre-loaded injector, is currently in the final phase of a U.S. IDE study, and has received the CE Mark in Europe. More information about Visiogen and the Synchrony technology can be found at [www.visiogen.com](http://www.visiogen.com).

More information on the company and its offerings can also be obtained by contacting:

Kate Jennings  
Maricich Brand Communications for Visiogen, Inc.  
Tel. 949-223-6455  
Fax 949-223-6451  
[kate@maricich.com](mailto:kate@maricich.com)

Kevin Hykes  
Chief Commercial Officer  
Visiogen, Inc.  
[info@visiogen.com](mailto:info@visiogen.com)